alexa Membranous nephropathy | Australia | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • Global Physicians and Healthcare Congress
    June 25-27, 2018 Dubai, UAE
  • International Conference on Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • 11th International Conference on Clinical and Medical Case Reports
    October 22-23, 2018 Istanbul, Turkey

Relevant Topics

Membranous Nephropathy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Membranous nephropathy


    Membranous nephropathy is a kidney disorder that leads to changes and inflammation of the structures inside the kidney that help filter wastes and fluids. The inflammation may lead to problems with kidney function. 

  • Membranous nephropathy

    Disease pathophysiology: 

    Neutral endopeptidase, a podocyte antigen that can digest biologically active peptides, was recently identified as the target antigen of antibodies deposited in the subepithelial space of glomeruli in a subset of patients with antenatal membranous nephropathy.


  • Membranous nephropathy

    Disease statistics:

    Membranous nephropathy (MGN) is one of the more common forms of nephrotic syndrome in the adult population. It can be idiopathicor secondary (30%). The two can be distinguished by clinical, laboratory, and histological features.


  • Membranous nephropathy

    Disease treatment:

    Diuretics help control edema. Loop diuretics are used most often.NSAIDs help to decrease the proteinuria. These have been largely supplanted by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). ACE inhibitors decrease proteinuria and control hypertension; use ARBs for patients intolerant of ACE inhibitors. Hepatic 3-methylglutaryl coenzyme A reductase inhibitors help treat hypercholesterolemia.


  • Membranous nephropathy

    Major research on disease:

    A low-salt diet is key to reducing anasarca. Protein restrictions may or may not be useful in reducing the rate of progression of chronic renal failure. Boston Team Developing PLA2R Antibody Test for Membranous Nephropathy.

Expert PPTs

Speaker PPTs

  • Hayam I Gad
    Effects of Pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of Diabetic nephropathy in an experimental model of diabetic renal disease
    PPT Version | PDF Version

High Impact List of Articles

Conference Proceedings